Expert Q&A - Articles - Page 15

EXPERT Q&A

Benzodiazepines: Dependence, Tolerance, and Addiction

May 1, 2016

Alex Stalcup, MD
Medical director of the New Leaf Treatment Center in Lafayette, CA.
Dr. Stalcup has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this
educational activity.

One good way to think of benzodiazepines is that they are literally, physiologically anyway, alcohol in a pill. Especially the fast-onset/fast-offset benzodiazepines like alprazolam (Xanax) have a very similar pharmacologic profile to alcohol. This discussion with Dr. Alex Stalcum covers strategies of using benzodiazepines as anxiety treatments for substance-abusing patients.

EXPERT Q&A

Poor Sleep in Children and Adolescents: A Primer

March 1, 2016

Rafael Pelayo, MD, FAASM

CCPR_DrPelayo_photo_Q&A.jpg Rafael Pelayo, MD.

Clinical Professor in the Department of Psychiatry and Behavioral Sciences, Stanford Center for Sleep Sciences and Medicine at the Stanford University School of Medicine, Stanford, CA.

Dr. Pelayo has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

The more important issue with sleep disorders is not so much the number of hours of sleep; it’s whether the child wakes up refreshed or not. Sleeping is about restoring the brain.Dr. Pelayo discusses his approach to treating sleep disorders, focusing on the key areas clinicians need to cover when getting a patient’s history.

EXPERT Q&A

What Psychiatrists Should Know About Sleep Medicine

September 1, 2015

Robert S. Rosenberg, DO, FCCP

Robert S. Rosenberg, DO, FCCP

Medical director of the Sleep Disorders Center of Prescott Valley, AZ, and author of Sleep Soundly Every Night, Feel Fantastic Every Day (Demos Medical Publishing, 201

Dr. Rosenberg has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

What basic questions should we be asking our patients who complain of sleep problems? We talk to Robert S. Rosenberg, DO, FCCP, to get his insight on sleep disorders, sleep apnea, restless leg syndrome, sleep studies, and benzodiazepines.

EXPERT Q&A

Anxiety Disorders in DSM-5 and Beyond

September 1, 2013

Daniel Pine, MD

Daniel Pine, MD

Chief, Section on Development and Affective Neuroscience, National Institute of Mental Health, Chair, DSM-5 Work Group on Child and Adolescent Psychiatric Disorders Dr. Pine has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity.

Dr Daniel Pine, chief of the section on Development and Affective Neuroscience at the NIMH and chair of the DSM-5 Work Group on Child and Adolescent Psychiatric Disorders discusses anxiety disorders in the current and future state of anxiety disorder research and practice.

EXPERT Q&A

Predicting Antidepressant Response

May 1, 2012

Andrew Leuchter, MD

Andrew Leuchter, MD

Professor of psychiatry, David Geffen School of Medicine, Director, Laboratory of Brain, Behavior, and Pharmacology, Semel Institute for Neuroscience and Human Behavior, University of California, Los Angeles
Dr. Leuchter has disclosed that he has been a paid consultant to NeoSync Inc. on the NeoSync EEG Synchronized TMS device (NEST). Dr. Balt has reviewed this article and found no evidence of bias in this educational activity.

I don’t think that there is any effective, proven way to predict medication response. I have been involved in research on biomarkers—we call them “response endophenotypes”—such as EEG, where we look at the physiologic response of the brain to a new drug and try to determine whether the drug will work for that patient.

EXPERT Q&A

The Neurobiology of Schizophrenia

March 1, 2009

Fredrik Jarskog, MD

Fredrik Jarskog, MD. Associate Professor of Clinical Psychiatry, Chief of Clinical Therapeutics Lieber Center for Schizophrenia Research and Treatment New York State Psychiatric Institute/Columbia University.

Dr. Jarskog has disclosed that he has no relevant relationships or financial interests in any commercial company pertaining to this educational activity. Dr. Jarskog has disclosed that glycine, D-serine, D-cycloserine, and Glu2/3 receptor agonists are not FDA-approved for the treatment of schizophrenia.

Dr. Jarskog, for many years the dopamine theory of schizophrenia has been dominant in the field. What is the current status of that theory?

EXPERT Q&A

Practical Issues in Using Transcranial Magnetic Stimulation

January 1, 2009

John O'Reardon, MD

TCPR-January-2009-TMS_JohnO'ReadonMD_Headshot.png

John O'Reardon, MD. Associate Professor of Psychiatry, University of Pennsylvania Health System.

Dr. O’Reardon has disclosed that he has received research grants from Neuronetics, Cyberonics, Cerex Biopharma, and Pfizer, and is on the speaker's bureaus of Eli Lilly and Bristol-Myers Squibb. Dr. Carlat has found that there is no evidence of commercial bias in this educational activity.

Dr. O’Reardon, the FDA recently approved TMS for depression. Can you clarify exactly what this approval was for?

EXPERT Q&A

Dr. John O’Reardon on Antidepressant Augmentation

January 1, 2004

John O'Reardon, MD

John O’Reardon, MD. Medical Director, Treatment Resistant Depression Clinic Associate Professor of Psychiatry, University of Pennsylvania School of Medicine

Dr. O'Reardon, you had mentioned at the end of our last interview (see TCR, Vol. 1, No. 1) some of the augmentation and combination strategies that you like to use in your clinic but we didn't have time to get into the actual specifics of these. To begin with, how do you decide when to augment? What kinds of drug failures do you try to establish?